DE69101634D1 - Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. - Google Patents

Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.

Info

Publication number
DE69101634D1
DE69101634D1 DE91903050A DE69101634A DE69101634D1 DE 69101634 D1 DE69101634 D1 DE 69101634D1 DE 91903050 A DE91903050 A DE 91903050A DE 69101634 A DE69101634 A DE 69101634A DE 69101634 D1 DE69101634 D1 DE 69101634D1
Authority
DE
Germany
Prior art keywords
blood factors
recombinantly produced
expressing
virus used
vaccina virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE91903050A
Other languages
English (en)
Other versions
DE69101634T2 (de
DE69101634T4 (de
Inventor
Falko-Guenter Falkner
Ross Macgillivray
Walter Bodemer
Friedrich Scheiflinger
Johann Eibl
Friedrich Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of DE69101634D1 publication Critical patent/DE69101634D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE91903050A 1990-01-26 1991-01-24 Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus. Expired - Fee Related DE69101634D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90101623 1990-01-26
PCT/EP1991/000139 WO1991011519A1 (en) 1990-01-26 1991-01-24 Recombinantly produced blood factors and process for the expression of said blood factors, as well as vaccinia virus recombinants used in said process

Publications (1)

Publication Number Publication Date
DE69101634D1 true DE69101634D1 (de) 1994-05-11

Family

ID=8203546

Family Applications (2)

Application Number Title Priority Date Filing Date
DE91903050A Expired - Fee Related DE69101634D1 (de) 1990-01-26 1991-01-24 Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE69101634T Expired - Lifetime DE69101634T4 (de) 1990-01-26 1991-01-24 Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69101634T Expired - Lifetime DE69101634T4 (de) 1990-01-26 1991-01-24 Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.

Country Status (12)

Country Link
EP (1) EP0512011B1 (de)
JP (1) JP2549224B2 (de)
AT (1) ATE103982T1 (de)
CA (1) CA2073859A1 (de)
CS (1) CS17291A2 (de)
DE (2) DE69101634D1 (de)
DK (1) DK0512011T3 (de)
ES (1) ES2052368T3 (de)
FI (1) FI923347A0 (de)
HU (1) HUT63459A (de)
NO (1) NO922953L (de)
WO (1) WO1991011519A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0561034B1 (de) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
DK0624199T3 (da) * 1991-12-31 1999-11-01 Zymogenetics Inc Fremgangsmåder til fremstilling af thrombin
US5527692A (en) * 1991-12-31 1996-06-18 Zymogenetics, Inc. Methods for producing thrombin
EP0728210B1 (de) * 1993-11-12 2005-04-13 Gilead Sciences, Inc. Thrombin mutanten
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
DE4430204A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
AT404357B (de) * 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
EP0796623B1 (de) * 1996-03-20 2005-05-25 Baxter Aktiengesellschaft Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1257295B1 (de) 2000-02-11 2009-04-15 Bayer HealthCare LLC Gerinnungsfaktor vii oder viia konjugate
EP1136553A1 (de) * 2000-03-22 2001-09-26 Octagene GmbH Herstellung von rekombinanten Blutgerinnungsfaktoren in humanen Zellinien
IL151857A0 (en) 2000-03-22 2003-04-10 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
CA2483478A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
DK1608745T3 (da) 2003-03-20 2009-06-15 Bayer Healthcare Llc FVII eller FVIIa-Varianter
NZ573412A (en) 2003-06-19 2010-09-30 Maxygen Holdings Ltd Factor VII or VIIa Gla domain variants
JP6245299B2 (ja) * 2016-04-27 2017-12-13 バクスアルタ ゲーエムベーハー 組換え安定細胞クローン、その産生およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
AU8339187A (en) * 1986-11-17 1988-06-16 New England Medical Center Hospitals, Inc., The Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
WO1989012685A1 (en) * 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants

Also Published As

Publication number Publication date
DE69101634T2 (de) 1994-08-18
JP2549224B2 (ja) 1996-10-30
EP0512011A1 (de) 1992-11-11
ATE103982T1 (de) 1994-04-15
DE69101634T4 (de) 1994-12-01
JPH05507401A (ja) 1993-10-28
ES2052368T3 (es) 1994-07-01
FI923347A (fi) 1992-07-23
CA2073859A1 (en) 1991-07-27
HUT63459A (en) 1993-08-30
EP0512011B1 (de) 1994-04-06
WO1991011519A1 (en) 1991-08-08
CS17291A2 (en) 1991-09-15
NO922953D0 (no) 1992-07-24
DK0512011T3 (da) 1994-05-09
FI923347A0 (fi) 1992-07-23
HU9202435D0 (en) 1992-10-28
NO922953L (no) 1992-09-04

Similar Documents

Publication Publication Date Title
DE69101634T4 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DK322188A (da) Fremgangsmaade til fremstilling af protein
DE68903846T2 (de) Neue galenische form von fenofibrat.
DE69529219T2 (de) Helicobacter proteine und impstoffe
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
DK106288A (da) Osteoinduktive praeparater
ES2152998T3 (es) Agente anticomplementario obtenido a partir de fucanos de algas pardas.
ATE79763T1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
FI871288A0 (fi) Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
UA35639C2 (uk) Спосіб одержання композиції очищеного капсидного білка вірусу папіломи людини
ATE6402T1 (de) Verfahren zur herstellung von hepatitis b oberflaechenantigen.
DE69129747D1 (de) In lösung bringen von proteinen in aktiver form
KR910003095A (ko) 사람의 단백질 c변이체 및 이의 제조방법
DE68920777D1 (de) Fluor enthaltende Copolymere, Verfahren zur Herstellung davon und Vernetzungszusammensetzungen.
DE3667960D1 (de) Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung.
DE69015945D1 (de) Verfahren zur Herstellung von p,p'-Biphenol.
PT91316A (pt) Processo para a preparacao de vectores recombinantes e de particulas hbsag recombinantes hibridas tendo as caracteristicas morfologicas do antigenio hbsag contendo uma sequencia imunogenica que induz anticorpos neutralizantes dirigidos contra hiv ou susceptivel de ser reconhecida por tais anticorpos
ATE37873T1 (de) Verfahren zur herstellung optisch aktiver 1,4dihydropyridine.
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
DE69003400D1 (de) Verfahren zur Herstellung von 4,4' Dihydroxydiphenylsulfon.
ATE452144T1 (de) Verfahren zur herstellung von humaneigenblutzytokinen
DK318086A (da) Praeparat til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadant praeparat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee